{\rtf1\ansi\deff0\deftab360

{\fonttbl
{\f0\fswiss\fcharset0 Arial}
{\f1\froman\fcharset0 Times New Roman}
{\f2\fswiss\fcharset0 Verdana}
{\f3\froman\fcharset2 Symbol}
}

{\colortbl;
\red0\green0\blue0;
}

{\info
{\author Biblio 7.x}{\operator }{\title Biblio RTF Export}}

\f1\fs24
\paperw11907\paperh16839
\pgncont\pgndec\pgnstarts1\pgnrestart
M.  Weinmueller, Rechenmacher, F., Marelli, U. Kiran, Reichart, F., Kapp, T. G., Raeder, A. F. B., Di Leva, F. Saverio, Marinelli, L., Novellino, E., Munoz-Felix, J. M., Hodivala-Dilke, K., Schumacher, A., Fanous, J., Gilon, C., Hoffman, A., and Kessler, H., ?Overcoming the lack of oral availability of cyclic hexapeptides: design of a selective and orally available ligand for the integrin alpha v beta 3?, Angewandte Chemie-International Edition, vol. 56, no. 51, pp. 16405-16409, 2017.\par \par F.  Reichart, Maltsev, O. V., Kapp, T. G., Raeder, A. F. B., Weinmueller, M., Marelli, U. Kiran, Notni, J., Wurzer, A., Beck, R., Wester, H. Juergen, Steiger, K., Di Maro, S., Di Leva, F. Saverio, Marinelli, L., Nieberler, M., Reuning, U., Schwaiger, M., and Kessler, H., ?Selective targeting of integrin alpha v beta 8 by a highly active cyclic peptide?, Journal of Medicinal Chemistry, vol. 62, no. 4, pp. 2024-2037, 2019.\par \par C. L.  Meena, Singh, D., Weinmueller, M., Reichart, F., Dangi, A., Marelli, U. Kiran, Zahler, S., and Sanjayan, G. J., ?Novel cilengitide-based cyclic RGD peptides as alpha nu beta(3) integrin inhibitors?, Bioorganic & Medicinal Chemistry Letters, vol. 30, no. 8, p. 127039, 2020.\par \par }